Glioblastoma Market Size in the 7MM was USD 799 million in 2021

The Glioblastoma market is expected to grow significantly owing to the use of Glioblastoma inhibitors in statin-intolerant patients, promising future strategies of Glioblastoma, and implications of Glioblastoma in broader therapy area. The Glioblastoma market companies are working like Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, and others.

Glioblastoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM market size from 2019 to 2032. The report also covers current Glioblastoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Glioblastoma Market Report

• The total market size of Glioblastoma in the 7MM is USD 799 million in 2021 and is projected to grow during the forecast period (2022-2032).

• According to the estimates, the highest market size of Glioblastoma is from the United States, in 2021.

• Among the EU4 (Germany, France, Italy, Spain), and the UK, in which Germany has the maximum revenue share in 2021 while Spain has the lowest market share.

• The market size of Glioblastoma in Japan is USD 58 million in 2021 which is expected to rise during the forecast period (2022-2032).

• The leading Glioblastoma Companies include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others.

• Promising Glioblastoma Pipeline Therapies includes Multiple dose of EO2401, PLX3397, Temozolomide, VXM01, Radiotherapy, Avelumab, Cilengitide, APVAC1 vaccine plus Poly-ICLC and GM-CSF, ALECSAT, G-202, APG101, MEDI-575, and others.

To discover which therapies are expected to grab the major Glioblastoma Market share, click here for Glioblastoma Market Research Report @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Latest Developmental Activities in the Glioblastoma Treatment Landscape

• In December 2017, the US FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent Glioblastoma that has progressed following prior therapy.

• In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved Temodal (R) (temozolomide) Capsules for the treatment of malignant glioma.

• In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan.

Glioblastoma Overview

Glioblastoma is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Glioblastoma is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. The exact underlying cause of Glioblastoma is unknown. Some cases may develop from existing, low-grade astrocytomas (malignant transformation) or they may occur without any evidence of a previous tumor (de novo).

Glioblastoma Epidemiology Segmentation in the 7MM
• Total Diagnosed Incident Population of Glioblastoma
• Gender-specific Diagnosed Incidence of Glioblastoma
• Type-specific Diagnosed Incidence of Glioblastoma
• Age-specific Diagnosed Incidence of Glioblastoma
• Diagnosed Incident Population based on Primary Site of Glioblastoma
• Diagnosed Incident Population based on Histologic Classification of Glioblastoma Tumor

Download the report to understand which factors are driving Glioblastoma epidemiology trends, click here for Glioblastoma epidemiology segmentation @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Marketed Drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells.
Temodar/Temodal: Merck

The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for Glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA.

Glioblastoma Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics
Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as Glioblastoma. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with Glioblastoma. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGlioblastoma. Currently, the drug has completed phase III stage of clinical development for the patients with rGlioblastoma
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with Glioblastoma.

Selinexor (KPT-330): Karyopharm Therapeutics
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name Xpovio for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision.

VBI-1901: VBI Vaccines
VBI-1901 is a cancer vaccine that VBI Vaccines has designed to treat Glioblastoma and medulloblastoma, which are two types of brain tumors. It is designed to kill Glioblastoma and medulloblastoma tumor cells infected with cytomegalovirus or CMV. While the immune system already targets cells infected by viruses, VBI-1901's goal is to boost their immune response such viruses. CMV inside tumor cells generate proteins called viral antigens that travel to the cells' surface. Currently, the vaccine is in phase I/II stage of clinical development for the patients with recurrent Glioblastoma and the company expects to initiate a randomized, controlled clinical study with registration potential in the fourth quarter of 2021. Recently, in June 2021, the company was granted Fast track designation by the FDA for VBI-1901 for the treatment of recurrent Glioblastoma.

ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
Immunomic Therapeutics (ITI) is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. ITI-1000 is currently being investigated in a phase II ATTAC-II trial for Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, and Glioblastoma and is funded by the National Cancer Institute.

Glioblastoma Market Outlook

Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The first step in treating glioblastoma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and to remove as much tumor as possible safely. Glioblastoma surgery is performed to achieve a "maximum safe resection," or removing as much of the tumor as possible without causing lasting neurological damage.

It is interesting to note that the emerging market of Glioblastoma includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-Glioblastoma-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The Glioblastoma pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and, others are some of the major players that are going to alter the market dynamics in the coming years.

To know more about Glioblastoma Medications, visit Glioblastoma Ongoing Clinical Trials @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glioblastoma Pipeline Report

• Coverage- 7MM

• Study Period- 2019-2032

• Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others.

• Glioblastoma Pipeline Therapies- Multiple dose of EO2401, PLX3397, Temozolomide, VXM01, Radiotherapy, Avelumab, Cilengitide, APVAC1 vaccine plus Poly-ICLC and GM-CSF, ALECSAT, G-202, APG101, MEDI-575, and others.

• Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers

To discover more about Glioblastoma Market Drugs in development, click here for Glioblastoma Market Dynamics and Glioblastoma Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Report Introduction
3. Glioblastoma Multiforme Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary of Glioblastoma Multiforme (GBM)
6. Key Events
7. SWOT Analysis
8. Disease Background and Overview: Glioblastoma Multiforme
9. Treatment
10. Guidelines and Recommendations from Different Organizations
11. Epidemiology and Patient Population
12. Patient Journey
13. Key Endpoints in Glioblastoma Multiforme
14. Marketed Products
15. Emerging Drugs
16. GBM: Seven Major Market Analysis
17. KOL Views
18. Unmet Needs
19. Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Glioblastoma Patient Population of the report, click here for Glioblastoma Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.